Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박영훈 | - |
dc.date.accessioned | 2024-05-20T16:31:05Z | - |
dc.date.available | 2024-05-20T16:31:05Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.other | OAK-34932 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268416 | - |
dc.description.abstract | Background: Hepatitis B virus reactivation (HBVr) is a well-known complication of systemic chemotherapy for particularly hematologic malignancies in HBV carriers. We performed a multicenter retrospective study to investigate the incidence and risk factors of HBVr in patients with hepatitis B surface antigen (HBsAg)-positive multiple myeloma (MM). Methods: We included 123 patients with HBsAg-positive MM who had received systemic therapy. The primary objective of the study was to evaluate the incidence of HBVr in patients with HBsAg-positive MM. Results: The median age was 59 years, and 72 patients were male. With a median follow-up duration of 41.4 months, there were 43 instances of HBVr in 35 patients (28.5%): 29 treatment-related HBVr occurred during 424 treatments. Treatments containing antiviral prophylaxis were associated with a significantly lower incidence of HBVr compared to those without (14.4% vs. 1.9%, P < 0.001). Moreover, treatment with cyclophosphamide (P = 0.002) and doxorubicin (P = 0.053) were risk factors for HBVr; stem cell transplantation was not associated with HBVr. There was no significant difference in overall survival between patients with and without HBVr (P = 0.753) and myeloma progression was the major cause of death. Conclusion: Considering the low incidence of HBVr in patients who had received antiviral prophylaxis, HBsAg-positivity should not impede patients from receiving optimal antimyeloma treatment or participating in clinical trials. © 2023 | - |
dc.language | English | - |
dc.publisher | Elsevier Inc. | - |
dc.subject | Hepatitis B virus | - |
dc.subject | Immune suppression | - |
dc.subject | Multiple myeloma | - |
dc.subject | Prophylaxis | - |
dc.subject | Reactivation | - |
dc.title | Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study | - |
dc.type | Article | - |
dc.relation.issue | 2 | - |
dc.relation.volume | 24 | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | e50 | - |
dc.relation.lastpage | e57.e2 | - |
dc.relation.journaltitle | Clinical Lymphoma, Myeloma and Leukemia | - |
dc.identifier.doi | 10.1016/j.clml.2023.10.004 | - |
dc.identifier.wosid | WOS:001171228900001 | - |
dc.identifier.scopusid | 2-s2.0-85176609469 | - |
dc.author.google | Yi | - |
dc.author.google | Jun Ho | - |
dc.author.google | Lee | - |
dc.author.google | Jung Lim | - |
dc.author.google | Yoo Jin | - |
dc.author.google | Kang | - |
dc.author.google | Hye Jin | - |
dc.author.google | Park | - |
dc.author.google | Young Hoon | - |
dc.author.google | Yuh | - |
dc.author.google | Young Jin | - |
dc.author.google | Lim | - |
dc.author.google | Sung-Nam | - |
dc.author.google | Kim | - |
dc.author.google | Hyo Jung | - |
dc.author.google | Jung | - |
dc.author.google | Sung-Hoon | - |
dc.author.google | Je-Jung | - |
dc.author.google | Cho | - |
dc.author.google | Hee Jeong | - |
dc.author.google | Moon | - |
dc.author.google | Joon Ho | - |
dc.author.google | Yhim | - |
dc.author.google | Ho-Young | - |
dc.author.google | Kihyun | - |
dc.contributor.scopusid | 박영훈(57212764446) | - |
dc.date.modifydate | 20240520120338 | - |